About: Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment
Creator	Danzi, Gian Loffi, Marco Moschini, Luigi Tano, Giuseppe Testa, Sophie
Source	Medline; PMC
abstract	INTRODUCTION: SARS-CoV-2 infection may predispose patients to thrombotic disease. Patients with COVID-19 pneumonia who are receiving non-vitamin K antagonists or direct oral anticoagulants for chronic disease are usually switched to heparin treatment during hospitalization. However, information about the most appropriate antithrombotic therapy after the acute infection phase is lacking. CASE DESCRIPTION: We report the case of a patient with chronic atrial fibrillation who was recently hospitalized for severe COVID-19 pneumonia. Four weeks after discharge he experienced an episode of an acute pulmonary embolism while on rivaroxaban therapy with adequate drug plasma levels, and in the absence of strong predisposing risk factors. CONCLUSION: This case highlights the risk of thrombotic complications after COVID-19 infection, raises some concern about their underlying mechanisms, and supports the use of effective anti-thrombotic therapy. LEARNING POINTS: COVID-19 infection is associated with frequent thrombotic events. A pro-coagulative status could be triggered by the persistent inflammatory phase of the infection despite anticoagulation. Adequate antithrombotic therapy is necessary for the prevention of acute and later thrombotic complications and needs close monitoring.
has issue date	2020-06-18(xsd:dateTime)
bibo:doi	10.12890/2020_001790
bibo:pmid	32665940
has license	cc-by-nc
sha1sum (hex)	e0f6d3235ae1bdcd86766b97d2d39425ee456f63
schema:url	https://doi.org/10.12890/2020_001790
resource representing a document's title	Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment
has PubMed Central identifier	PMC7350955
has PubMed identifier	32665940
schema:publication	Eur J Case Rep Intern Med
resource representing a document's body	covid:e0f6d3235ae1bdcd86766b97d2d39425ee456f63#body_text
is schema:about of	named entity 'COVID-19' named entity 'infection' named entity 'However' named entity 'discharge' named entity 'heparin' named entity 'antithrombotic' named entity 'strong' named entity 'atrial fibrillation' named entity 'thrombotic complications' named entity 'SARS-CoV-2' named entity 'rivaroxaban' named entity 'COVID-19' named entity 'vitamin K antagonists' named entity 'antithrombotic' named entity 'pneumonia' named entity 'Internal Medicine' named entity 'Rivaroxaban' named entity 'inflammatory' named entity 'pulmonary arteries' named entity 'empiric' named entity 'DVT' named entity 'direct oral anticoagulants' named entity 'losartan' named entity 'thrombotic complications' named entity 'fibrinogen' named entity 'DOACs' named entity 'inflammatory response' named entity 'LMWH' named entity 'interstitial pneumonia' named entity 'therapeutic level' named entity 'thrombosis' named entity 'infection' named entity 'LMWH' named entity 'Autopsy' named entity 'C-reactive protein' named entity 'inflammatory markers' named entity 'aPTT' named entity 'antithrombotic' named entity 'thrombotic' named entity 'anticoagulation treatment' named entity 'COVID' named entity 'ferritin' named entity 'rivaroxaban' named entity 'low molecular weight heparin' named entity 'rivaroxaban' named entity 'LMWH' named entity 'emergency department' named entity 'Lower limb' named entity 'pulmonary artery' named entity 'infection' named entity 'COVID-19' named entity 'chest pain' named entity 'mg/dl' named entity 'troponin' named entity 'immunomodulatory' named entity 'endothelium' named entity 'mmHg' named entity 'DOAC' named entity 'subacute' named entity 'rivaroxaban' named entity 'SARS-CoV-2' named entity 'complete blood count' named entity 'acute infection' named entity 'anticoagulation therapy' named entity 'coagulative' named entity 'DOACs' named entity 'plasma levels' named entity 'heparin' named entity 'COVID' named entity 'antithrombotic agents' named entity 'infection' named entity 'acute infection' named entity 'anticoagulant therapy' named entity 'SpO2' named entity 'anti-hypertensive' named entity 'anticoagulation' named entity 'ventricle'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software